Cagrilintide: the long-acting amylin analog that adds a second appetite-regulation signal to semaglutide — and what Phase III says about the combination.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk, fatty acid-conjugated for extended half-life and once-weekly dosing. It is being evaluated primarily in combination with semaglutide as "CagriSema" — the rationale being that amylin and GLP-1 regulate appetite through distinct hypothalamic pathways, and combining them could produce additive weight loss beyond what either achieves alone. Phase III CagriSema data showed roughly 22–25% weight loss — data that is reshaping how the obesity pharmacology field thinks about combination peptide approaches.
- Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic β-cells. It regulates satiety via calcitonin receptor/RAMP complexes in the area postrema and hypothalamus.
- Cagrilintide is a modified amylin analog with a fatty acid chain enabling albumin binding and weekly half-life — analogous to the design approach used for semaglutide.
- Phase II data showed ~10% weight loss with cagrilintide monotherapy at 4.5 mg weekly (PMID: 34379949).
- CagriSema Phase III: ~22–25% body weight reduction at 68 weeks — exceeding tirzepatide benchmarks in some analyses.
- Not yet approved; regulatory submissions expected 2025–2026.
- Distinct from pramlintide (Symlin), the short-acting amylin analog already approved for type 1 and 2 diabetes.
Amylin biology: a satiety signal distinct from GLP-1
Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide co-secreted alongside insulin from pancreatic β-cells in response to meals. Its primary physiological roles:
- Satiety signaling. Amylin acts on calcitonin receptors (CTR) complexed with receptor activity-modifying proteins (RAMPs) — particularly RAMP1 and RAMP3 — in the area postrema (AP) and nucleus tractus solitarius (NTS) in the brainstem. This produces satiety signals that reduce meal size and eating rate.
- Gastric emptying slowing. Similar to GLP-1, amylin slows gastric emptying — reducing the rate of nutrient absorption and post-meal glucose peaks.
- Glucagon suppression. Amylin suppresses glucagon release after meals, contributing to postprandial glucose regulation.
The key distinction from GLP-1: amylin and GLP-1 activate different receptors and signal through different brain circuits. GLP-1 receptors are expressed in hypothalamic arcuate nucleus neurons (NPY/AgRP and POMC neurons); amylin/CTR/RAMP complexes signal primarily through the hindbrain (AP and NTS). Combining both activates complementary satiety circuits, which is the mechanistic basis for the additive weight loss hypothesis.
Cagrilintide's design: extending amylin half-life
Native amylin has a short half-life (~20 minutes), similar to native GLP-1. Pramlintide (Symlin) — the approved amylin analog — requires three times daily injection. Cagrilintide solves this via a fatty acid chain conjugated to the amylin analog backbone, enabling reversible binding to serum albumin and extending half-life to approximately 7 days (once-weekly injection).
This design mirrors semaglutide's fatty acid approach. The modification also required some sequence changes to the amylin peptide backbone to reduce aggregation propensity — amylin is inherently amyloidogenic (pancreatic amyloid deposits in type 2 diabetes are composed of IAPP aggregates). Cagrilintide's modifications suppress this aggregation while maintaining receptor activity.
Phase II and Phase III clinical evidence
Cagrilintide's clinical development has been rapid and results-positive:
- Phase II monotherapy (STEP-1 equivalence study): Cagrilintide 4.5 mg weekly produced ~10% weight loss at 26 weeks in overweight/obese adults without diabetes — comparable to older GLP-1 monotherapies (PMID: 34379949).
- CagriSema Phase II combination: Cagrilintide 2.4 mg + semaglutide 2.4 mg weekly over 32 weeks produced ~15% weight loss — exceeding semaglutide monotherapy at 12 weeks by several percentage points, with dose escalation continuing.
- CagriSema Phase III (REDEFINE trials): Published data indicates ~22–25% weight loss at 68 weeks in the full dose combination — data that competes with the highest tirzepatide results and represents potentially best-in-class weight loss from a weekly injectable combination.
Nausea and GI side effects from CagriSema are similar to or modestly higher than semaglutide alone — consistent with the additive mechanism bringing additive GI effects alongside additive weight loss.
Cagrilintide vs. pramlintide: the design comparison
Pramlintide (Symlin), approved since 2005, is a short-acting amylin analog requiring TID injection. Its clinical uptake has been limited precisely because of this dosing burden. Cagrilintide's once-weekly design solves the adherence problem. The weight loss from CagriSema substantially exceeds what pramlintide adds to insulin regimens (~3–4 kg in diabetic patients). This is the commercial and clinical case for cagrilintide over the existing amylin therapy.